- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06905587
Metilfenidato en sobrevivientes de tumor cerebral pediátrico con fatiga relacionada con el cáncer (EMBRAIN)
Efecto del metilfenidato en la fatiga relacionada con el cáncer en pacientes tratados para un tumor cerebral durante la infancia o adolescencia: protocolo para un ensayo cruzado aleatorizado, doble ciego, controlado con placebo: el ensayo Embrain
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).
If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sebastian W Most-Mottelson, MD, PhD Student
- Número de teléfono: +45 21567257
- Correo electrónico: sebastian.wenzel.most-mottelson@rsyd.dk
Copia de seguridad de contactos de estudio
- Nombre: Mathias Rathe, Consultant, MD, PhD
- Número de teléfono: +45 20469682
- Correo electrónico: mathias.rathe@rsyd.dk
Ubicaciones de estudio
-
-
-
Aalborg, Dinamarca, 9000
- Reclutamiento
- Aalborg University Hospital
-
Contacto:
- Christina Friis Jensen, Consultant, MD
- Número de teléfono: +45 97663368
- Correo electrónico: cfj@rn.dk
-
Investigador principal:
- Christina Friis Jensen, Consultant, MD
-
Aarhus, Dinamarca, 8200
- Reclutamiento
- Aarhus University Hospital
-
Contacto:
- Louise T Henriksen, MD, PhD
- Número de teléfono: +45 20921611
- Correo electrónico: louhen@rm.dk
-
Investigador principal:
- Louise T Henriksen, MD, PhD
-
Copenhagen, Dinamarca, 2100
- Reclutamiento
- Rigshospitalet
-
Contacto:
- Christine Dahl, Consultant, MD, PhD
- Número de teléfono: +45 35454137
- Correo electrónico: christine.dahl@regionh.dk
-
Investigador principal:
- Christine Dahl, Consultant, MD, PhD
-
Odense, Dinamarca, 5000
- Reclutamiento
- Odense University Hospital
-
Contacto:
- Mathias Rathe, Consultant, MD, PhD
- Número de teléfono: +45 20469682
- Correo electrónico: mathias.rathe@rsyd.dk
-
Investigador principal:
- Sebastian W Most-Mottelson, MD, PhD Student
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
- Treated for a brain tumor during the previous 10 years.
- Age ≥6 years and <28 years at the start of the trial.
- Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
- No known signs of clinical or radiological tumor progression at last follow-up.
- Danish is the sole or primary language (enabling provision of validated assessment tools).
- Patient and family have provided consent for inclusion in the trial.
- Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
- History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.
Exclusion Criteria:
-
Any known contraindications to methylphenidate as outlined below:
A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.
-
History of recent poorly controlled seizures.
-
Complex tics or Tourette syndrome (including family history of tic disorder).
-
Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.
-
Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.
-
Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.
-
Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.
-
Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).
-
Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Methylphenidate, Then Placebo
Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
|
Experimental: Placebo, Then Methylphenidate
Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
Periodo de tiempo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS). |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
Periodo de tiempo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS. |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
|
Behaviour Rating Inventory of Executive Function (BRIEF)
Periodo de tiempo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire. |
At baseline, at Week 6, and Week 16.
|
|
Connor's Continuous Performance Test (CPT) Online Suite
Periodo de tiempo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Coding
Periodo de tiempo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Digit Span
Periodo de tiempo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
PedsQL Generic Core Scales
Periodo de tiempo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported measures of Health Related Quality of Life. |
At baseline, at Week 6, and Week 16.
|
|
Accelerometry (Axivity AX3)
Periodo de tiempo: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used. |
Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
|
Barkley's Stimulant Side Effect Rating Scale (SSERS)
Periodo de tiempo: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used. |
At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Mathias Rathe, Consultant, MD, PhD, Odense University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias por sitio
- Neoplasias del Sistema Nervioso
- Neoplasias del Sistema Nervioso Central
- Neoplasias
- Neoplasias Cerebrales
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Ácidos carboxílicos
- Piperidinas
- Ácidos, carbocíclicos
- Fenilacetatos
- Metilfenidato
Otros números de identificación del estudio
- 24/51848
- R352-A20781 (Otro número de subvención/financiamiento: The Danish Cancer Society)
- 2023-001094 (Otro número de subvención/financiamiento: The Danish Childhood Cancer Foundation)
- 2023-507926-18-00 (Ctis)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .